Source: Washington Post
by Gary Winslett
“By now, you’ve probably heard about the weight-loss benefits of GLP-1 drugs like Ozempic (semaglutide) and Mounjaro (tirzepatide), but scientists are still discovering that they have all kinds of other benefits too: They help prevent strokes and heart attacks, fight kidney disease and Parkinson’s, curb addiction, and lower risks for several particularly nasty cancers. At this rate, just about every American will have some condition or risk factor that makes these drugs look appealing in their lifetime. And when that day comes, they should be able to get it. Universal access to GLP-1s should be the explicit goal of our federal government. This is not some left-wing fantasy; it’s a smart economic policy.” (08/21/25)